{"preliminary_commentary":{"by_channel":{"x_thread":9,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03171025\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["nivolumab"]],"indication":"localized muscle-invasive bladder cancer","name":"NEXT","nct_id":"NCT03171025","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=next-nct03171025. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NEXT","arms":[{"description":null,"label":"Nivolumab, all patients","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2027-10-31","type":"ESTIMATED"},"conditions":["Bladder Cancer"],"enrollment":{"count":200,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Nivolumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-01-07","lead_sponsor":"University of Utah","official_title":"A Phase II Open Label Single Arm Study of Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-02-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Two-year rate of failure-free survival (FFS)","timeFrame":"2 years"}],"references":[{"citation":"Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, Schuetz E, Sanchez A, O'Neil B, Poch M, Li R, Lloyd S, Tward J, Phunrab T, Hawks JL, Swami U, Boucher KM, Agarwal N, Gupta S. Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). J Immunother Cancer. 2025 Mar 18;13(3):e010572. doi: 10.1136/jitc-2024-010572.","pmid":"40102029","type":"DERIVED"}],"start_date":{"date":"2017-07-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT03171025"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/next-nct03171025"}